BioArctic二季度Leqembi权利金增长但利润转亏，合作进展多为已披露事项汇总

Oil prices slide over 2% amid hopes for progress in Mideast diplomacy
Introduction & Market Context
BioArctic AB (STO:BIOA B) presented its second quarter 2026 results on August 26, highlighting growing Leqembi royalties and expanded strategic partnerships despite a modest operating loss in the period. The Swedish neuroscience company’s shares fell 5.1% to $327.40 following the presentation, trading between its 52-week range of $257 to $364.40.
The quarter marked a transition toward more predictable recurring revenues, with Leqembi royalties reaching SEK 179.4 million and new collaboration agreements validating the company’s BrainTransporter platform technology. While net revenues of SEK 248 million appeared flat year-over-year, the comparison was skewed by a SEK 223 million milestone payment received in Q2 2025.
Quarterly Performance Highlights
BioArctic’s financial performance in Q2 2026 reflected the evolving nature of its business model. The company reported a small operating loss of SEK 6 million, compared to a profit of SEK 179 million in the prior-year quarter, primarily due to the absence of milestone payments and increased research spending.
As shown in the following chart of BioArctic’s royalty performance, Leqembi revenues demonstrated consistent quarterly growth throughout the trailing five quarters.
Recurring revenues approached SEK 200 million per quarter, driven by Leqembi royalties of SEK 179.4 million—up 12% sequentially and 27% year-over-year. The company also recognized SEK 51 million from a Novartis upfront payment during the quarter, with an additional $30 million upfront from Eli Lilly received in July after the period ended.
Operating expenses increased to SEK 232 million from SEK 193 million, with research and development accounting for approximately 75% of costs. Management indicated that underlying operating costs are expected to continue rising as the project portfolio advances, though the company still anticipates full-year 2026 profitability.
The detailed operating performance breakdown illustrates the company’s investment in growth initiatives.
Leqembi Commercial Momentum
Global sales of Leqembi, BioArctic’s Alzheimer’s disease treatment developed with partner Eisai, reached ¥29.3 billion (approximately $184 million) in Q2 2026, representing 12% sequential growth and 27% year-over-year growth. The drug’s performance varied significantly by region, with the United States leading growth at ¥15.5 billion, up 13% from Q1 2026.
China emerged as the fastest-growing market with sales of ¥4.8 billion, up 17% sequentially, while Japan remained flat at ¥6.1 billion, down 6% from the prior quarter. The company attributed U.S. growth to simplified diagnostic procedures and the August 2026 launch of Iqlik, the subcutaneous autoinjector formulation for initiation treatment.
The following chart illustrates Leqembi’s sales trajectory and Eisai’s forecast through fiscal year 2026.
Eisai projects full-year fiscal 2026 Leqembi sales of ¥143.5 billion (approximately $910 million), representing 63% growth from fiscal 2025. This forecast corresponds to approximately SEK 880 million in royalties for BioArctic over the 12-month period from Q2 2026 to Q1 2027.
The presentation highlighted several recent regulatory approvals and launches expanding Leqembi’s global footprint.
Key developments included FDA approval of the subcutaneous formulation on July 13, 2026, with U.S. launch in August, and expected Japanese approval in Q3 2026 with reimbursement anticipated in Q4. China filed for priority review with approval expected in the first half of 2027. The drug also launched in Australia, Belgium, Brazil, and India during Q2.
Clinical Validation and Real-World Evidence
Real-world data from the LEADER study presented at the Alzheimer’s Association International Conference (AAIC) 2026 provided additional validation for Leqembi’s clinical profile. The interim analysis of 432 patients across 13 U.S. clinical practices demonstrated strong efficacy and safety outcomes.
The study showed that 82.5% of patients were stable or improved, while 78.9% of those treated for more than 18 months transitioned to maintenance treatment and remained on therapy. Safety data aligned with the product label, with severe ARIA-E (amyloid-related imaging abnormalities-edema) occurring in just 0.2% of patients, compared to total ARIA rates of 12.3%.
Strategic Partnerships and Platform Validation
BioArctic’s partnership portfolio represents a significant source of potential future value, with total deal values exceeding $3 billion across five major collaborations. The presentation emphasized partnerships as "a key component behind our success."
The most significant recent development was a new collaboration with Eli Lilly valued at up to $800 million plus royalties, with $770 million in milestones remaining. This agreement focuses on neurodegeneration and provides strong external validation of BioArctic’s proprietary BrainTransporter platform, which enables therapeutic molecules to cross the blood-brain barrier.
The company’s strategic collaboration strategy is further illustrated by its expanding partnerships.
A new collaboration with Mesenkia Therapeutics marks BioArctic’s first expansion into oncology, specifically targeting glioblastoma. Under this agreement, BioArctic will produce a novel BrainTransporter-based drug candidate targeting HVEM, a protein found on certain glioblastoma tumor cells including tumor stem cells.
Other major partnerships include Novartis ($802 million potential value with $772 million remaining), Bristol Myers Squibb ($1.35 billion potential with $1.25 billion remaining), and the foundational Eisai collaboration (EUR 222 million with 9% royalties and EUR 34 million remaining).
Pipeline Expansion and Technology Platforms
BioArctic positioned itself as a "world-leading innovator in precision neurology" based on two core technology platforms: highly selective antibodies targeting aggregated forms of toxic proteins, and the BrainTransporter platform for delivering biotherapeutics across the blood-brain barrier.
The company’s comprehensive R&D pipeline spans multiple neurodegenerative diseases and now extends into oncology.
Key pipeline developments in Q2 2026 included positive progress for exidavnemab, an alpha-synuclein antibody for Parkinson’s disease and multiple system atrophy (MSA). The Phase 2a EXIST study safety review confirmed a favorable safety profile, supporting progression into Phase 2b studies in MSA and Parkinson’s disease-related dementia expected to initiate in the first half of 2027.
The mechanism of action for the alpha-synuclein program demonstrates the scientific rationale behind the therapeutic approach.
For BAN2238, a BrainTransporter-coupled alpha-synuclein antibody, IND-enabling activities are underway with clinical development planned for 2027. The company also expanded its project portfolio to include programs targeting TDP-43 for ALS, Huntington’s disease, Gaucher’s disease, and the new oncology collaboration.
Financial Position and Outlook
BioArctic maintained a strong balance sheet with SEK 2.0 billion in cash, cash equivalents, and short-term investments at the end of Q2 2026. This position strengthened to more than SEK 2.3 billion after receiving the $30 million Lilly upfront payment in July.
Operating cash flow was SEK 138 million in Q2, including a EUR 20 million sales milestone payment from Eisai received in May. The company paid a dividend of SEK 177 million (SEK 2 per share) in June.
Management guided for full-year 2026 operating costs to increase 40% to 60% from 2025 levels, though the increase is expected to land near the low end of that range. Despite rising costs, the company maintained its expectation for full-year profitability.
The presentation outlined several near-term catalysts that could drive future performance.
Key upcoming events include potential Japanese approval and reimbursement for the subcutaneous formulation in Q3-Q4 2026, Chinese approval expected in Q1 2027, full Phase 2a readout for exidavnemab in Q4 2026, and initiation of exidavnemab Phase 2b studies in Q2 2027. Additional regulatory approvals and launches for Leqembi are expected across multiple markets, along with potential partnership milestones.
Strategic Positioning and Key Takeaways
BioArctic’s presentation emphasized four strategic pillars supporting its 2030 ambitions: Leqembi commercial growth, broader pipeline development, strategic partnerships, and strong financial position.
Chief Executive Gunilla Osswald characterized the company as "among world leaders in two different areas," referring to its antibody technology and BrainTransporter platform. Chief R&D Officer Johanna Fälting noted that "Lilly’s selection of the BrainTransporter for next generation CNS therapies provide a strong validation from a leading pharmaceutical company."
Chief Commercial Officer Anna Grönblad highlighted that Medicare Part D coverage beginning in January 2027 "will clearly be a commercial game changer" for U.S. Leqembi uptake.
The company faces several challenges, including competitive pressure in the Alzheimer’s market, uneven regional performance particularly in Japan and Europe, rising operating costs, and execution risk in its earlier-stage pipeline programs. However, the transition toward recurring royalty revenues, expanding partnership validation of its technology platforms, and strong cash position provide a foundation for continued investment in its growing pipeline.
With a P/E ratio of 138, the market is pricing in significant growth expectations. The company’s ability to deliver on its pipeline programs, particularly exidavnemab in Parkinson’s disease and the expanding BrainTransporter collaborations, will be critical to justifying this valuation over the coming quarters.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.